Can Type 1 Diabetes Be Slowed Down? A New Perspective on an Old Drug
What happened
A recent study suggests that anti-thymocyte globulin (ATG), a drug long used in transplantation, may slow the progression of type 1 diabetes.
Importantly, low doses appear to provide similar benefits with fewer side effects.
How it works
Type 1 diabetes is an autoimmune condition where the immune system attacks insulin-producing beta cells.
ATG works by:
- reducing T-cell activity
- dampening autoimmune responses
- modulating immune balance
What it means for patients
- this is not a cure
- it may slow disease progression
- benefits are greatest early in the disease
Can it be used outside clinical trials?
Currently:
- ATG is not a standard treatment for type 1 diabetes
- it is mainly used in clinical research settings
- it requires medical supervision due to immunosuppression risks
Link to viruses and autoimmunity
There is growing interest in the role of viruses such as:
- Epstein–Barr virus (EBV)
- HHV-6 and HHV-7
These viruses may contribute to immune dysregulation and trigger autoimmune responses.
This supports a broader therapeutic concept: combining immune modulation with addressing potential triggers.
Conclusion
ATG is not a cure, but it demonstrates that modifying the course of autoimmune diseases is possible.
This content is for informational purposes only and does not constitute medical advice.
Sources and research
- News overview (LiveScience)
- TrialNet — Type 1 Diabetes clinical research network
- Diabetes Care — peer-reviewed clinical research
- PubMed Central — biomedical literature database
This material is based on publicly available scientific data and clinical studies. It is provided for informational purposes only and does not constitute medical advice.
АС